These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 16123514)

  • 1. Thiazolidinediones and lowered HDL cholesterol.
    Savage RL; Kiuru A
    Diabetes Care; 2005 Sep; 28(9):2329-30. PubMed ID: 16123514
    [No Abstract]   [Full Text] [Related]  

  • 2. Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment.
    Shetty C; Balasubramani M; Capps N; Milles J; Ramachandran S
    Diabet Med; 2007 Jan; 24(1):94-7. PubMed ID: 17227331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol.
    Normén L; Frohlich J; Montaner J; Harris M; Elliott T; Bondy G
    Diabetes Care; 2004 Sep; 27(9):2241-2. PubMed ID: 15333491
    [No Abstract]   [Full Text] [Related]  

  • 4. High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate.
    Keidar S; Guttmann H; Stam T; Fishman I; Shapira C
    Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1192-4. PubMed ID: 17636555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe hypo-alpha-lipoproteinemia during treatment with rosiglitazone.
    Sarker A; Semple RK; Dinneen SF; O'Rahilly S; Martin SC
    Diabetes Care; 2004 Nov; 27(11):2577-80. PubMed ID: 15504988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe HDL-c reduction during rosiglitazone therapy in an obese woman with type 2 diabetes.
    Almeida RL; Fedrizzi P; Fedrizzi D; Almeida TS
    Arq Bras Endocrinol Metabol; 2010 Oct; 54(7):663-7. PubMed ID: 21085773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atherogenic index of plasma [log(triglycerides/HDL-cholesterol)]: theoretical and practical implications.
    Dobiásová M
    Clin Chem; 2004 Jul; 50(7):1113-5. PubMed ID: 15229146
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14).
    Spanheimer R; Betteridge DJ; Tan MH; Ferrannini E; Charbonnel B;
    Am J Cardiol; 2009 Jul; 104(2):234-9. PubMed ID: 19576353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
    Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
    Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
    Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No improvement of high-density lipoprotein (HDL) vasorelaxant effect despite increase in HDL cholesterol concentration in type 2 diabetic patients treated with glitazones.
    Perségol L; Duvillard L; Monier S; Brindisi MC; Bouillet B; Petit JM; Vergès B
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E2015-9. PubMed ID: 25137425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia].
    Im M; Kim M; Lee JK; Chang YH; Lee DY; Hong SI; Lee YY; Hong YJ
    Korean J Lab Med; 2010 Feb; 30(1):17-9. PubMed ID: 20197717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone for treatment of HIV lipodystrophy.
    Mikhail N
    Ann Intern Med; 2004 Nov; 141(9):739; author reply 739-40. PubMed ID: 15520438
    [No Abstract]   [Full Text] [Related]  

  • 14. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.
    Goldberg RB; Kendall DM; Deeg MA; Buse JB; Zagar AJ; Pinaire JA; Tan MH; Khan MA; Perez AT; Jacober SJ;
    Diabetes Care; 2005 Jul; 28(7):1547-54. PubMed ID: 15983299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Troglitazone directly increases HDL cholesterol levels.
    Nozue T; Michishita I; Minagawa F; Genda A
    Diabetes Care; 1999 Feb; 22(2):355-6. PubMed ID: 10333957
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of pioglitazone on diabetes-related outcomes in Hispanic patients.
    Jun JK; Gong WC; Mathur R
    Am J Health Syst Pharm; 2003 Mar; 60(5):469-73. PubMed ID: 12635453
    [No Abstract]   [Full Text] [Related]  

  • 18. Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.
    Odom J; Williamson B; Carter L
    Am J Health Syst Pharm; 2008 Oct; 65(19):1846-50. PubMed ID: 18796427
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pioglitazone protects the type-2-diabetes patient from myocardial infarction and stroke].
    MMW Fortschr Med; 2007 Aug; 149(31-32):52-3. PubMed ID: 17849787
    [No Abstract]   [Full Text] [Related]  

  • 20. Paradoxically decreased HDL-cholesterol levels associated with rosiglitazone therapy.
    Gutschi LM; Malcolm JC; Favreau CM; Ooi TC
    Ann Pharmacother; 2006 Sep; 40(9):1672-6. PubMed ID: 16912247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.